top of page

Turning back the clock on fibrosis

Small molecule inhibitors for reversal of fibrosis

First in class novel inhibitors targeting a central pathway in fibrosis and inflammation

Inosi is developing therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function.

 

Inosi’s technology is based on collaborative research from the founding team at Monash University, the Monash Biomedicine Discovery Institute ,and the Monash Institute of Pharmaceutical Sciences.

​

IP Group helped spin-out the company and provided seed investment.

Our Partners

IP Group Logo
Monash_Logo_white_900ppi.png

Fibrosis is a global problem with high unmet need

45%

deaths linked to fibrosis

10%

of the population have a fibrotic condition

0

drugs able to reverse fibrosis

bottom of page